A microphysiological system model of therapy for liver micrometastases

Metastasis accounts for almost 90% of cancer-associated mortality. The effectiveness of cancer therapeutics is limited by the protective microenvironment of the metastatic niche and consequently these disseminated tumors remain incurable. Metastatic disease progression continues to be poorly understood due to the lack of appropriate model systems. To address this gap in understanding, we propose an all-human microphysiological system that facilitates the investigation of cancer behavior in the liver metastatic niche. This existing LiverChip is a 3D-system modeling the hepatic niche; it incorporates a full complement of human parenchymal and non-parenchymal cells and effectively recapitulates micrometastases. Moreover, this system allows real-time monitoring of micrometastasis and assessment of human-specific signaling. It is being utilized to further our understanding of the efficacy of chemotherapeutics by examining the activity of established and novel agents on micrometastases under conditions replicating diurnal variations in hormones, nutrients and mild inflammatory states using programmable microdispensers. These inputs affect the cues that govern tumor cell responses. Three critical signaling groups are targeted: the glucose/insulin responses, the stress hormone cortisol and the gut microbiome in relation to inflammatory cues. Currently, the system sustains functioning hepatocytes for a minimum of 15 days; confirmed by monitoring hepatic function (urea, α-1-antitrypsin, fibrinogen, and cytochrome P450) and injury (AST and ALT). Breast cancer cell lines effectively integrate into the hepatic niche without detectable disruption to tissue, and preliminary evidence suggests growth attenuation amongst a subpopulation of breast cancer cells. xMAP technology combined with systems biology modeling are also employed to evaluate cellular crosstalk and illustrate communication networks in the early microenvironment of micrometastases. This model is anticipated to identify new therapeutic strategies for metastasis by elucidating the paracrine effects between the hepatic and metastatic cells, while concurrently evaluating agent efficacy for metastasis, metabolism and tolerability.

[1]  G. Hannon,et al.  Patient-derived tumor xenografts: transforming clinical samples into mouse models. , 2013, Cancer research.

[2]  Genee Y. Lee,et al.  Three-dimensional culture models of normal and malignant breast epithelial cells , 2007, Nature Methods.

[3]  M. Junttila,et al.  Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.

[4]  Andrej J. Savol,et al.  Modeling Boundary Conditions for Balanced Proliferation in Metastatic Latency , 2013, Clinical Cancer Research.

[5]  J. Rautela,et al.  The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. , 2013, Cancer research.

[6]  F. Oesch,et al.  Generation of human hepatocytes by stem cell technology: definition of the hepatocyte , 2005, Expert opinion on drug metabolism & toxicology.

[7]  F. Schildberg,et al.  Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice , 2012, Hepatology.

[8]  R. Tompkins,et al.  Long‐Term in Vitro Function of Adult Hepatocytes in a Collagen Sandwich Configuration , 1991, Biotechnology progress.

[9]  M. Smyth,et al.  The pre-metastatic niche: finding common ground , 2013, Cancer and Metastasis Reviews.

[10]  Kristen M. Naegle,et al.  An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells. , 2008, Molecular bioSystems.

[11]  J. Aguirre-Ghiso,et al.  Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.

[12]  F. Guengerich,et al.  Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. , 1991, The Journal of pharmacology and experimental therapeutics.

[13]  Alan Wells,et al.  Partial Mesenchymal to Epithelial Reverting Transition in Breast and Prostate Cancer Metastases , 2012, Cancer Microenvironment.

[14]  Vito Pistoia,et al.  Fasting Cycles Retard Growth of Tumors and Sensitize a Range of Cancer Cell Types to Chemotherapy , 2012, Science Translational Medicine.

[15]  L. Fu,et al.  The circadian clock: pacemaker and tumour suppressor , 2003, Nature Reviews Cancer.

[16]  Alan Wells,et al.  Novel three-dimensional organotypic liver bioreactor to directly visualize early events in metastatic progression. , 2007, Advances in cancer research.

[17]  Julio A. Aguirre.  Models, mechanisms and clinical evidence for cancer dormancy , 2007 .

[18]  D. Bernabé,et al.  Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells , 2011, Brain, Behavior, and Immunity.

[19]  K. Hunter,et al.  Modeling metastasis in vivo. , 2004, Carcinogenesis.

[20]  Alan Wells,et al.  Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance , 2011, Clinical & Experimental Metastasis.

[21]  H. Borer,et al.  [Liver metastasis?]. , 1999, Schweizerische medizinische Wochenschrift.

[22]  R. M. Simpson,et al.  Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. , 2010, Cancer research.

[23]  Douglas A Lauffenburger,et al.  Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities. , 2011, Integrative biology : quantitative biosciences from nano to macro.

[24]  J. Maher,et al.  Support of cultured hepatocytes by a laminin-rich gel. Evidence for a functionally significant subendothelial matrix in normal rat liver. , 1987, The Journal of clinical investigation.

[25]  S. Bhatia,et al.  In vitro zonation and toxicity in a hepatocyte bioreactor. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[26]  M. Rubin,et al.  E-cadherin expression in primary carcinomas of the breast and its distant metastases , 2003, Breast Cancer Research.

[27]  A. Wells,et al.  E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas , 2008, Clinical & Experimental Metastasis.

[28]  J. Darnell,et al.  Dependence of liver-specific transcription on tissue organization , 1985, Molecular and cellular biology.

[29]  A. Rajasekaran,et al.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. , 2006, Cancer research.

[30]  J. Hengstler,et al.  Human hepatocytes: isolation, culture, and quality procedures. , 2012, Methods in molecular biology.

[31]  David J Beebe,et al.  Hedgehog signaling in myofibroblasts directly promotes prostate tumor cell growth. , 2012, Integrative biology : quantitative biosciences from nano to macro.

[32]  J. Brugge,et al.  Use of Three-Dimensional Basement Membrane Cultures to Model Oncogene-Induced Changes in Mammary Epithelial Morphogenesis , 2004, Journal of Mammary Gland Biology and Neoplasia.

[33]  Hidekazu Takagi,et al.  Hepatic Stellate Cells Promote Liver Metastasis of Colon Cancer Cells by the Action of SDF-1/CXCR4 Axis , 2009, Annals of Surgical Oncology.

[34]  B. Davidson,et al.  A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: the effects of prior exposure to chemotherapy. , 2006, Journal of hepatology.

[35]  Claudia Fischbach,et al.  Microfluidic culture models of tumor angiogenesis. , 2010, Tissue engineering. Part A.

[36]  N. Bird,et al.  Role of Kupffer cells in the outgrowth of colorectal cancer liver metastases , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[37]  Celeste M Nelson,et al.  Tissue geometry patterns epithelial–mesenchymal transition via intercellular mechanotransduction , 2010, Journal of cellular biochemistry.

[38]  Walker Inman,et al.  Liver tissue engineering in the evaluation of drug safety , 2009, Expert opinion on drug metabolism & toxicology.

[39]  Michael K. Wendt,et al.  Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer , 2011, Molecular biology of the cell.

[40]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[41]  Franziska Hirschhaeuser,et al.  Lactate: a metabolic key player in cancer. , 2011, Cancer research.

[42]  Paul A. Khavari,et al.  Invasive 3-Dimensional Organotypic Neoplasia from Multiple Normal Human Epithelia , 2010, Nature Medicine.

[43]  D. Redelmeier,et al.  Translation of research evidence from animals to humans. , 2006, JAMA.

[44]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[45]  Alan Wells,et al.  All-human microphysical model of metastasis therapy , 2013, Stem Cell Research & Therapy.

[46]  J. O’Shaughnessy.  Extending survival with chemotherapy in metastatic breast cancer. , 2005, The oncologist.

[47]  C. Meyer,et al.  Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor β–induced apoptosis , 2009, Hepatology.

[48]  K. Asano,et al.  Continued high albumin production by multicellular spheroids of adult rat hepatocytes formed in the presence of liver-derived proteoglycans. , 1989, Biochemical and biophysical research communications.

[49]  Jong Hwan Sung,et al.  A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. , 2009, Lab on a chip.

[50]  M. Yarmush,et al.  A microfluidic hepatic coculture platform for cell-based drug metabolism studies. , 2010, Biochemical pharmacology.

[51]  Jayanta Debnath,et al.  Modelling glandular epithelial cancers in three-dimensional cultures , 2005, Nature Reviews Cancer.

[52]  S. Caritis,et al.  A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS. , 2013, Journal of pharmaceutical and biomedical analysis.

[53]  B. Teicher.  Tumor models for efficacy determination , 2006, Molecular Cancer Therapeutics.

[54]  F. Alvarez,et al.  Long-term culture of adult rat hepatocyte spheroids. , 1992, Experimental cell research.

[55]  D. Stolz,et al.  Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin , 2007, British Journal of Cancer.

[56]  Albert Goldbeter,et al.  Implications of circadian clocks for the rhythmic delivery of cancer therapeutics , 2008, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[57]  S. Sahoo,et al.  3-D tumor model for in vitro evaluation of anticancer drugs. , 2008, Molecular pharmaceutics.

[58]  Chandana Mohanty,et al.  A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs , 2012, Molecular vision.

[59]  Adam S. Hayward,et al.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME , 2013, Archives of Toxicology.

[60]  I. N. Crispe,et al.  The liver as a lymphoid organ. , 2009, Annual review of immunology.

[61]  G. Michalopoulos,et al.  Three-dimensional culture of hepatocytes in a continuously flowing medium , 1998, In Vitro Cellular & Developmental Biology - Animal.

[62]  Ueli Schibler,et al.  Circadian rhythms: mechanisms and therapeutic implications. , 2007, Annual review of pharmacology and toxicology.

[63]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[64]  Daniel A Fletcher,et al.  Tissue Geometry Determines Sites of Mammary Branching Morphogenesis in Organotypic Cultures , 2006, Science.

[65]  D. Nolan,et al.  Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis , 2008, Science.

[66]  D. Tarin,et al.  The fallacy of epithelial mesenchymal transition in neoplasia. , 2005, Cancer research.

[67]  Alan Wells,et al.  Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition , 2010, Molecular Cancer.

[68]  R. Weinberg.  The many faces of tumor dormancy. , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[69]  E. Thompson,et al.  Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. , 2006, Cancer research.

[70]  R L Slaughter,et al.  Recent Advances: the Cytochrome P450 Enzymes , 1995, The Annals of pharmacotherapy.

[71]  R. Wells.  The role of matrix stiffness in regulating cell behavior , 2008, Hepatology.

[72]  Trey Ideker,et al.  Bioengineering and Systems Biology , 2006, Annals of Biomedical Engineering.

[73]  S. Ohdo.  Circadian rhythms in the CNS and peripheral clock disorders: chronopharmacological findings on antitumor drugs. , 2007, Journal of pharmacological sciences.

[74]  Gerhard Christofori,et al.  Mouse models of breast cancer metastasis , 2006, Breast Cancer Research.

[75]  Valerie M. Weaver,et al.  Three-dimensional context regulation of metastasis , 2008, Clinical & Experimental Metastasis.